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Small intestinal bacterial overgrowth (SIBO) is a heterogenous and poorly understood
entity characterised by an excessive growth of select microorganisms within the small
intestine. This excessive bacterial biomass, in turn, disrupts host physiology in a myriad of
ways, leading to gastrointestinal and non-gastrointestinal symptoms and complications.
SIBO is a common cause of non-specific gastrointestinal symptoms in children, such
as chronic abdominal pain, abdominal distention, diarrhoea, and flatulence, amongst
others. In addition, it has recently been implicated in the pathophysiology of stunting, a
disease that affects millions of children worldwide. Risk factors such as acid-suppressive
therapies, alterations in gastrointestinal motility and anatomy, as well as impoverished
conditions, have been shown to predispose children to SIBO. SIBO can be diagnosed via
culture-dependant or culture-independent approaches. SIBO’s epidemiology is limited
due to the lack of uniformity and consensus of its diagnostic criteria, as well as the
paucity of literature available. Antibiotics remain the first-line treatment option for SIBO,
although emerging modalities such as probiotics and diet manipulation could also have
a role. Herein, we present a state-of-the-art-review which aims to comprehensively
outline the most current information on SIBO in children, with particular emphasis on
the gut microbiota.
Keywords: small intestine bacterial overgrowth, small intestinal bacterial overgrowth, small bowel bacterial
overgrowth, proton pump inhibitors, gut microbiota, stunting
INTRODUCTION
Small intestinal bacterial overgrowth (SIBO) is a heterogenous disorder characterised by an
excessive growth of select microorganisms within the small intestine. This excessive bacterial
biomass, in turn, disrupts host physiology in a myriad of ways, leading to gastrointestinal and
non-gastrointestinal symptoms and complications (1). SIBO is a common cause of non-specific
gastrointestinal symptoms in children, such as chronic abdominal pain, abdominal distention,
diarrhoea, and flatulence, amongst others (2–5). In addition, it has recently been implicated in
the pathophysiology of stunting (6), a disease that affects millions of children worldwide. Certain
risk factors, such as acid-suppressive therapies (7–10), alterations in gastrointestinal motility and
anatomy (11–20), and impoverished conditions (21–26), have been shown to predispose children
to SIBO. Despite the relatively high prevalence of SIBO in children, it remains a poorly understood
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disorder. In fact, only a small number of studies have been
published in the last two decades. Since the year 2000, only 149
articles have been published on paediatric SIBO (Figure 1). Due
to this previous scarcity of literature and the recent emergence
of novel, informative data regarding the underpinnings of the
disease, an update for practicing paediatricians is now warranted.
This article represents a state-of-the-art review which aims to
comprehensively outline the most current information on SIBO
in children, with particular emphasis on the gut microbiota.
SEARCH STRATEGY AND SELECTION
CRITERIA
In December 2018, two investigators systematically searched
the PubMed/MEDLINE, EBSCOhost, Google Scholar, and
ResearchGate databases using the primary search blocks “small
intestine bacterial overgrowth OR small intestinal bacterial
overgrowth OR small bowel bacterial overgrowth AND children”
and “small intestine bacterial overgrowth OR small intestinal
bacterial overgrowth OR small bowel bacterial overgrowth.”
In addition, the following terms were used in combination:
“small intestinal bacterial overgrowth,” “pathophysiology,”
“16S rRNA sequencing,” “next generation sequencing,” “gut
microbiota,” “proton pump inhibitors,” “juvenile systemic
FIGURE 1 | Number of paediatric SIBO publications on PubMed from 2000 to
2019. PubMed literature search with the entry block “(children OR pediatrics)
AND (small intestinal bacterial overgrowth OR small intestine bacterial
overgrowth OR small bowel bacterial overgrowth)”; the search was conducted
on March 26, 2019.
sclerosis,” “scleroderma,” “ileocecal valve,” “vitamin,” “functional
gastrointestinal disorders,” “chronic abdominal pain,” “irritable
bowel syndrome,” “constipation,” “hydrogen,” “methane,”
“breath test,” “stunted,” “environmental enteric dysfunction,”
“environmental enteropathy,” “Methanobrevibacter smithii,”
“methanogens,” “immunodeficiency,” and “coeliac disease.” The
search was restricted to titles and abstracts written in English
and Spanish, and no date range restriction was applied. We also
searched for ongoing clinical trials in Clinicaltrials.gov with
the term “small intestinal bacterial overgrowth.” Adult patient
studies were included when relevant. In addition, we screened
the reference lists of the selected papers and created weekly alerts
on PubMed to enhance the sensitivity of the search. The last
literature search was conducted on May 13th, 2019.
THE GASTROINTESTINAL TRACT AND
THE GUT MICROBIOTA
Each of the organs and anatomical portions of the gastrointestinal
system provides specific functions and are equipped with
mechanisms to promote a homeostatic relationship with
its indigenous bacterial community (microbiota) (27, 28).
This mutualistic homeostasis is achieved through mechanisms
including gastric and bile acids, pancreatic and digestive
secretions, intestinal motility, the barrier function of the
ileocecal valve, amongst others. Within the lumen of the
gastrointestinal tract resides the gut microbiota, a complex
and susceptible microbial consortium composed of enteric-
adapted bacteria, which is acquired in the very early stages
of life and develops in concert with the host. The “sterile
womb hypothesis” refers to the notion that the neonate
acquires the gut microbiota during birth through ingestion
of the mother’s vaginal (vaginal delivery) or skin (caesarean
section) microbiota. In contrast, although increasing evidence
has suggested that the infant gut microbiota is acquired in utero,
a technically comprehensive multimodal investigation recently
failed to detect any placenta dwelling microorganisms (29). The
gut microbiota maintains a life-long symbiotic relationship with
the human host, providing a plethora of important functions;
from vitamin and short-chain fatty acid (SCFA) production
to immunoregulation and neuropeptide secretion [for review
see (30)].
The composition and functionality of the gut microbiota
is shaped and influenced by a multitude of intrinsic and
extrinsic factors, such as genetics, mode of delivery, gestational
age, feeding type and diet, pharmaceuticals, and exercise (30).
The composition of the gut microbiota exhibits variations
related to the anatomical portion studied, which is mainly
influenced by factors such as the luminal oxygen concentration
and pH. Indeed, bacterial numbers increase from about
103 to 104/ml in the stomach to approximately 1011/ml
in the colon (Figure 2) (31–33). The colonic microbiota
is the largest prokaryotic community in the human body,
representing nearly the 0.3% of the overall host body weight
(34). Although composed largely of four bacterial phyla –
Actinobacteria, Firmicutes, Bacteroidetes, and Proteobacteria–
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FIGURE 2 | Gastrointestinal tract features and bacterial composition and content. Created with BioRender.com.
the infantile gut microbiome is dominated by Actinobacteria,
with Firmicutes emerging to dominate after infancy (35). In
general, bacteria from the Actinobacteria (e.g., Bifidobacterium),
Firmicutes (e.g., Faecalibacterium, Clostridium, Ruminococcus,
Lactobacillus) and Bacteroidetes (e.g., Bacteroides, Prevotella)
phyla are largely regarded as commensal microorganisms, while
a significant portion of gastrointestinal pathogens belong to the
Proteobacteria phylum (e.g., Escherichia, Shigella, Salmonella,
Klebsiella, and Helicobacter, amongst others) (36, 37). In
addition to this diverse community of bacteria, the human
gastrointestinal tract is also home to an extensive array
of viruses (38), fungi (39), and archaea (40). While it
remains unclear at present as to whether the former two
kingdoms play a significant role in SIBO pathogenesis,
methanogenic archaea, such as Methanobrevibacter spp., have
been directly implicated in a methane-specific form of the
disorder (41).
It is important to note, however, that despite the substantial
advances made in the study of the gut microbiota in general,
the small bowel microbiota remains poorly understood (42).
Whereas the colonic microbiota is more easily accessible
and can be sampled via colonoscopy or faecal sample
(43), sampling of the small bowel microbiota poses a
major challenge due to the invasiveness of the procedures
(upper endoscopy) and the technical difficulties associated
with these. Therefore, this significantly obscures our
understanding of SIBO and hampers the establishment
of a definition.
THE EPIDEMIOLOGY OF SIBO IN
CHILDREN
The prevalence of SIBO in children has been explored in a
wide spectrum of clinical contexts, including children living in
impoverished conditions, individuals with chronic abdominal
pain (CAP), as well as those who suffer from irritable bowel
syndrome (IBS), stunting, and obesity, amongst other diseases.
SIBO prevalence ranges from about 9% in children taking proton
pump inhibitors (PPIs) (7) to approximately 90% in those with
stunted growth (6) and chronic abdominal pain (CAP) (2).
However, it should be noted that the data on the epidemiology
of SIBO in children is limited by the small number of studies
available, the lack of appropriate controls in some studies, and the
varying test methodology and diagnostic cut-offs applied.Table 1
shows the study characteristics and reported SIBO prevalence in
children with a wide variety of clinical contexts and risk factors.
SIBO PATHOGENESIS
SIBO can negatively impact the host in a range of ways (1, 31, 53–
61). These include bacterial carbohydrate fermentation leading
to excess gas and water production (1); bacterial deconjugation
of bile acids resulting in poorly absorbed liposoluble vitamins
(18); bacterial macronutrient and micronutrient consumption
(bacterial-host nutrient competition), leaving the host with less
available nutrients for absorption (58); villous blunting leading
to carbohydrate malabsorption (13, 62–64); decreased short
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TABLE 1 | Study characteristics and reported SIBO prevalence in children with a wide variety of clinical contexts and risk factors.
References Year Study population Study design Sample size
(n)




Pignata et al. (44) 1990 Children with immunodeficiency





Jejunal aspirate cultures (not
performed in controls due to ethical
reasons). Positivity was defined as
≥105 CFU/ml.
GHBT
Cut-off point was defined as 10 ppm.
Jejunal aspirate:
Cases: 41%
Pereira et al. (21) 1991 Children under the age of 5 years
living a rural village in Myanmar.
Cross-sectional Cases: 340 LHBT
Positivity was defined as “a transient
breath hydrogen peak at the 20, 40,
or 60min breath samples following
the lactulose test meal, and
distinguishable from the later
colonic peak”.
27.2%
de Boissieu et al. (3) 1996 Children with chronic diarrhoea,
abdominal pain, or both, aged 2
months to 12 years.
Prospective Cases: 53 GHBT.
Positivity was defined as a H2 value
≥10 ppm over baseline after
ingestion of glucose.
34%










Fontanele Soares et al.
(20)
2005 Children with chronic
constipation aged 3 to 13 years.
Cross-sectional Cases: 40 CH4 breath test
Positivity (methane producers) was
defined as a methane concentration
< 3 ppm.
73.5%
Dos Reis et al. (22) 2007 Children living in a slum and age
and sex-matched controls aged
5 to 11 years.
Cross-sectional Cases: 50
Controls: 50
Glucose and lactulose H2 breath
tests.
Positivity was defined as an increase






Fridge et al. (12) 2007 Children and adults with CF and
pancreatic insufficiency (mean




Glucose H2/CH4 breath test.
Positivity was defined as either a
fasting H2 ≥15 ppm, a rise of ≥10
ppm over baseline at any time during
the test, or a doubling of baseline
CH4 excretion at any time during the
test.
CH4 excretors were defined by a




Scarpellini et al. (45) 2009 Children with IBS (Rome II




Lactulose H2/CH4 breath test.
Positivity was defined as an early rise
in H2 or CH4 excretion of >20 ppm




Lisowska et al. (11) 2009 Children with cystic fibrosis and
controls with gastrointestinal
symptoms aged 5 to 17 years.
Cross-sectional Cases: 62
Controls: 390
Glucose H2/CH4 breath test.
Positivity was defined as a fasting H2
or CH4 level of ≥20 ppm and ≥10
ppm, respectively; or an increase in
H2 or CH4 over baseline during the




Collins et al. (46) 2010 Children with CAP (Rome II





Positivity was defined as a rise in H2




Cole et al. (16) 2010 Children younger than 2 years
with short bowel syndrome
receiving enteral feeds
Prospective Cases: 10 GHBT
Positivity was defined as either an
increased fasting breath H2 ≥ 20
ppm or increase from baseline of ≥10
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TABLE 1 | Continued
References Year Study population Study design Sample size
(n)




Leiby et al. (15) 2010 Children with secondary retentive
faecal incontinence (and
radiographically diagnosed
faecal impaction) aged 6 to 12





Lactulose H2/CH4 breath test.
[n] Positivity was defined as an
increase in H2 ≥20 ppm or in CH4
≥10 ppm over baseline at ≤60min.
Patients were considered CH4
producers if their level was more than
3 ppm at any point in the study; and
high basal CH4 was diagnosed if the
baseline sample was >10 ppm.
Cases: 42%
Controls: 23%
Jones et al. (47) 2011 Children with chronic diarrhoea
and/or abdominal pain and/or
bloating and/or irritability younger
than 15 years of age.
Cross-sectional Cases: 287 CO2-corrected H2 and CH4 levels
Positivity was defined as an increase
in H2 >10 ppm over baseline in the
initial 45min of the test.
Patients were classified as H2 or CH4
producers if they produced >10 ppm
of these gases at any time point.
87%
Mello et al. (23) 2012 Children of poor socioeconomic
conditions residing in a slum and
children of socioeconomically




Lactulose H2/CH4 breath test.
Positivity was defined as an increase
in H2 of ≥ 20 ppm or CH4 of ≥ 10
ppm with respect to the fasting value








Gutierrez et al. (17) 2012 Children with intestinal failure and
refractory gastrointestinal
symptoms (i.e., abdominal
bloating, emesis, diarrhoea, or
increased stoma output) with a
median age of 5 years.
Cross-sectional Cases: 57 Duodenal aspirate cultures.
Positivity was defined as a bacterial
growth of ≥105 CFU/ml.
70%
Scarpellini et al. (48) 2013 Children with IBS (Rome II
criteria).
Study objective: to assess the
effects of rifaximin treatment on
SIBO
prevalence and gastrointestinal
symptoms in children affected
by IBS.
Prospective Cases: 50 Lactulose H2/CH4 breath test.
Positivity was defined as an early rise
in H2 or CH4 excretion >20 ppm
within the first 90min.
66%
Ojetti et al. (14) 2013 Children with myelomeningocele
and constipation.
Cross-sectional Cases: 18 Lactulose H2/CH4 breath test.
Positivity was not specified.
39%
Hegar et al. (9) 2013 Children with epigastric pain and
a normal baseline GHBT aged
≥5 years were divided into two
4-week trial groups: group 1
(cases): omeprazole plus
Lacidofil® (1.9 × 109 CFU
Lactobacillus rhamnosus R0011
and 0.1 × 109 CFU
Lactobacillus acidophillus
R0052); and group 2 (controls):
omeprazole plus placebo
capsule.
Study objective: to evaluate the
incidence of SIBO in children
treated with omeprazole and to









Positive test was defined as an
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TABLE 1 | Continued
References Year Study population Study design Sample size
(n)




Rosen et al. (8) 2014 Children taking acid suppressive
therapy for a minimum of 4
weeks (PPIs and histamine-2
antagonists) and controls (no









Korterink et al. (4) 2014 Children with abdominal
pain–related functional
gastrointestinal disorders
(AP-FGID; Rome III criteria) aged
6 to 18 years.
Prospective Cases: 161 GHBT.
Positivity was defined as fasting
breath H2 concentration ≥20 ppm or
increase in H2 ≥12 ppm over
baseline value.
14.3%
Lisowska et al. (49) 2014 Children with progressive familial
intrahepatic cholestasis aged 8
to 25 years.
Prospective Cases: 26 Glucose H2/CH4 breath test.
Positivity was defined as a high
baseline value (>20 ppm for
hydrogen or >10 ppm for methane)
or an early increase of gas excretion
(>12 ppm for hydrogen or >6 ppm
for methane).
35%
Sieczkowska et al. (10) 2015 Children with histology-proven
peptic esophagitis aged 3 to 18
years.
Study objective: to evaluate
whether a 3-month PPI
treatment regimen induces
SBBO in children and if so, to
determine
associated symptoms.
Prospective Cases: 40 Glucose H2/CH4 breath test.
Positivity was defined as an increase
in H2 of ≥10 over baseline.
22.5%
Donowitz et al. (25) 2016 Bangladeshi children from an
impoverished neighbourhood
aged 2 years.
Cross-sectional Cases: 90 GHBT.
Positivity was defined as an increase
in H2 of ≥12 ppm over baseline.
16.7%
Cares et al. (7) 2017 Children taking PPIs for longer
than 6 months’ duration and
controls (no PPI treatment) aged
3 to 17 years.
Study objective: to measure the
risk for SIBO in children on
chronic PPI therapy and
compare, using the glucose
HBT, the frequency of SIBO in




Glucose H2/CH4 breath test.
Positivity was defined as an increase





Wang et al. (50) 2017 Children with autism spectrum
disorder and age- and
sex-matched healthy controls
(age was not specified)
Cross-sectional Cases: 310
Controls: 1240
Glucose H2/CH4 breath test.
Positivity was defined as an increase
in H2 of ≥20 ppm or CH4 of ≥10





Mello et al. (24) 2017 Children of low socio-economic
status living in an urban slum
aged 5 to 11 years
Cross-sectional Cases: 100 Lactulose H2/CH4 breath test.
Positivity was defined as an increase
in H2 of ≥20 ppm or CH4 of ≥10
ppm over baseline before the first
60min.
Real-time polymerase chain reaction
(results are described in
aetiology section)
61.0%
Belei et al. (51) 2017 Children with overweight or
obesity aged 10 to 18 years and




Positivity was defined as an increase
in H2 in two consecutive
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TABLE 1 | Continued
References Year Study population Study design Sample size
(n)




Galloway et al. (18) 2018 Children with intestinal failure
aged 9 months to 17 years.
Prospective Cases: 14 Duodenal aspirate culture.
Positivity was defined as
≥105 CFU/ml.
43%
Gaffar et al. (26) 2018 Children living in a
disadvantaged urban community
aged 12 to 18 months.
Prospective Cases: 194 GHBT
Positivity was defined as an increase
in H2 of ≥12 ppm over baseline
measurement on any single
post-glucose reading.
14.9%




Cases: 79 Glucose H2/CH4 breath test.
Positivity was defined as either a H2
basal level of ≥12 ppm, a peak of H2
excretion of ≥10 ppm over baseline
during the test, or a CH4 level of ≥12
ppm at any point time.
31.6%
Vonaesch et al. (6) 2018 Stunted children aged 2 to 5
years and healthy controls.
Cross-sectional Cases: 46 Duodenal aspirate culture.
Positivity was defined as ≥105
CFU/ml.
16S rRNA sequencing (results are
described in the text)
Cases: 96%
*A few studies also evaluated the incidence of SIBO in children (indicated in parenthesis). GHBT, glucose hydrogen breath test; LHBT, lactulose hydrogen breath test; H2, hydrogen;
CH4, methane; CO2, carbon dioxide; ppm, parts per million.
chain fatty acid production (6, 65); intestinal and systemic
inflammation (16, 25, 66); and increased gut permeability
(Figure 3). It should be noted that a recent systematic review
(53) and clinical study (25) found conflicting and contradictory
evidence supporting effects of gut permeability.
RISK FACTORS FOR SIBO
Acid-Suppressive Therapies
Gastric acid plays a crucial role in preventing pathogens from
colonizing the human alimentary tract, particularly the proximal
portions (67). Several extrinsic and intrinsic factors are known
to alter this natural barrier (68), with one of them being
medication-induced hypochloridria, caused most frequently by
proton pump inhibitors (PPIs). PPIs are commonly prescribed
for the treatment of gastroesophageal reflux disease (GERD)
and, sometimes, for gastroesophageal reflux (GER) in children
(69). These drugs decrease gastric acid secretion by blocking
the enzyme H+/K+-adenosine triphosphatase located in the
apical membrane of parietal cells (70). It has been estimated
that approximately 34% (69) of paediatric patients treated with
PPIs develop adverse effects, including infectious diarrhoea,
Clostridium difficile infection, respiratory infections, or SIBO
(71–77). In addition, PPIs have also been shown to alter
the faecal gut microbiota of children and adults (78, 79). In
theory, the resultant acid suppression creates a more favourable
environment for bacteria to overgrow –particularly Gram-
positive, aerobic bacteria (31)–, leading to the development
of SIBO. However, a recent observational study (6) found
contradictory evidence: despite the high prevalence of SIBO seen
in the patient cohort (i.e., 96%), gastric pH was found to be in
the acidic range (i.e., pH 2.7). It is important to note that pH
measurements were only obtained from the study group and
lacked normal reference values for comparison.
To date, four studies have assessed SIBO risk in children
taking acid-suppressive treatments (80). Cares et al. (7) used
the glucose H2/CH4 breath test to determine the presence of
SIBO in children taking PPIs for a prolonged time (i.e., longer
than 6 months). 77% of patients took a PPI for over 12 months,
and SIBO was diagnosed in 8.9% and 3.7% of PPI-subjects
and controls, respectively. Moreover, Sieczkowska et al. (10)
enrolled children with histology-proven peptic esophagitis in a 3-
month trial of omeprazole treatment. A glucose hydrogen breath
test (GHBT) was performed before and after PPI treatment,
revealing that 22.5% developed SIBO as a result of the therapy.
Furthermore, Rosen et al. (8) cultured the gastric fluid of children
taking PPIs for at least 4 weeks and whose last dose was taken
within 24 h of sampling. Compared to the control group, the
PPI-group was found to have a significantly higher prevalence
of gastric overgrowth (18 vs. 46%, respectively), mainly caused
by potential pathogens such as Staphylococcus and Streptococcus.
In a double-blind, placebo-controlled randomised clinical trial,
Hegar et al. (9) randomly assigned children to one of two 4-week
treatment groups: omeprazole+ placebo group or omeprazole+
probiotic. SIBO had been excluded at baseline in all. Following
the 4-week intervention, a second GHBT indicated that SIBO
was present in 33% and 26% of omeprazole/probiotic group and
omeprazole/placebo group, respectively.
Two metanalyses (81, 82) of adult patients evaluated the
association between PPI therapy and SIBO risk. The most recent
study by Su et al. (81) included 19 observational studies with a
total of 7,055 adult subjects in the analysis. Although there was a
significant degree of heterogeneity amongst the studies included,
after adjusting for study quality, the authors concluded that PPI
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FIGURE 3 | Mechanisms through which SIBO affects the host. The dotted arrows indicate increased intestinal permeability. * Includes vitamin A, D, E, and vitamin B
12. Vitamin K is synthesised by the gut microbiota, and thus its deficiency in this context is very unlikely. BA, bile acids; UBA, unconjugated bile acids; LPS,
liposaccharides. Created with BioRender.com.
therapy was associated with a moderately increased risk for SIBO
(odds ratio 1.71, 95% CI 1.20–2.43). The second meta-analysis
(83) included 11 studies [all of which were included in the
metanalysis by Su et al. (81)] with a total of 3,134 adult subjects.
Again, the authors found a statistically significant association
(odds ratio, 2.282, 95% CI 1.238–4.205) between PPI therapy and
SIBO, but only when diagnosis was made with “highly accurate
testing modality,” such as duodenal/jejunal aspirate culture. It is
important to mention, however, that all the studies included in
both metanalyses were observational in nature and culture or
breath test-based approaches were used for SIBO diagnosis.
In conclusion, it appears that acid suppressive therapies, and
in particular PPIs, seem to be a risk factor for SIBO development,
but only when this is assessed by culture approaches. However,
it is important to mention that the data are limited by the
overall low odds ratios (∼2) and the lack of controls. Thus, until
better data are available, it is of paramount importance that PPI
prescriptions in children with possible GERD are judicious, and
perhaps more importantly, that their use is avoided in children
with GER (72, 83).
Intestinal Motility Disturbances
In addition to the acidic environment created by the gastric acid,
gut motility is critical to preventing SIBO. One motor event,
the migrating motor complex (MMC), a cyclic motor pattern
that occurs during the interdigestive state, plays an important
role in preventing the development of bacterial overgrowth
within the small intestine (83). In fact, the MMC is commonly
referred to as the “intestinal housekeeper,” emphasising its role
in gastrointestinal health (84). Under physiological conditions,
the MMC sustains the aboral progression of luminal content in
the small intestine between meals, thereby preventing stasis and
SIBO. On this basis, an absent or disrupted MMC may lead to
bacterial overgrowth (84).
The typical example of a disease with gut dysmotility leading
to SIBO is systemic sclerosis, with ∼40% of adult patients
being affected (54). Despite the relatively high prevalence of
gastrointestinal symptoms in children with juvenile systemic
sclerosis (jSS) (85), to our knowledge, no studies have
investigated the association of SIBO with jSS.
A somewhat more common example of gut dysmotility
associated with increased risk of SIBO is cystic fibrosis (CF)
(86). Here there is limited clinical data from studies in children.
Lisowska et al. (11) found a significantly higher SIBO prevalence
in patients with CF compared with non-CF subjects (37 vs.
13%, respectively), and so did Fridge et al. (12) who found a
significantly higher prevalence in CF-subjects than controls (56
vs. 20%, respectively). Both studies used the hydrogen breath
test (HBT) for SIBO diagnosis. Moreover, Lewindon et al. (13)
evaluated, with the HBT, SIBO prevalence and orocecal transit
time of children with CF. Interestingly, compared with the two
control groups (i.e., healthy children and non-CF patients), CF-
subjects had a significantly higher SIBO prevalence and their
orocecal transit times were significantly longer than those of
healthy individuals. More recently, Furnari et al. (52) found
a 31% SIBO prevalence in both children and adults with CF.
Preclinical studies in murine models have demonstrated that
CF-mice have a higher SIBO prevalence than wild-type mice
(87), which is thought to be mainly caused by two factors:
(1) slowed intestinal transit –possibly due to unabsorbed lipids
leading to a triggering of the “ileal brake”– and/or smooth muscle
dysfunction (86, 88); and (2) mucus accumulation which acts
as an anchor for bacteria, thereby facilitating their overgrowth
(87, 89). Thus, the multifactorial nature of CF, including gut
dysmotility and impaired mucus clearance, seems to put patients
at a higher risk of SIBO development.
Constipation has been shown to be associated with SIBO.
However, the causative or consequential nature of this interaction
is unclear. In theory, a slower orocecal transit in constipation
may fail to clear the luminal content, thereby increasing SIBO
risk. On the other hand, methane, a biologically active gas
produced instead of hydrogen by some individuals from bacterial
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fermentation of carbohydrates, can delay intestinal transit, which
in turn may lead to constipation. We identified three studies
that investigated the role of SIBO in children with constipation.
Ojetti et al. (14) diagnosed SIBO in 39% (7/18) of children
with myelomeningocele, a disease associated with constipation.
Interestingly, the authors found that all methane producers had
a delayed orocecal transit time. Moreover, Leiby et al. (15)
found a 42% (21/50) SIBO prevalence in children with retentive
faecal incontinence, of whom, eight had methanogenic SIBO,
11 had hydrogen-type SIBO, and two had mixed (methane
and hydrogen)-type SIBO. In addition, 48% of patients with
faecal incontience were found to have high basal methane
concentrations (>10 ppm) as compared with 10% of control
subjects. Furthermore, Fontanele Soares et al. (20) investigated
the relationship between methane production and colonic transit
time in children with constipation. Methane production was
found in 73.5% (25/34) of children with constipation and soiling
as compared with 1% of children with constipation alone.
The notion that a slowed intestinal transit may predispose to
SIBO is supported by two recent studies in adults (90, 91). In the
most recent study, by Revaiah et al. (90), two patient groups (i.e.,
PPI-group and PPI+ prokinetic group) underwent a GHBT and
lactulose hydrogen breath test (LHBT) and orocecal transit time
assessment. Interestingly, SIBOwas documentedmore frequently
in the PPI alone group than in the PPI + prokinetic group, and
SIBO-positive patients had slower orocecal transit times than
SIBO-negative patients. However, it is important to note that the
overall SIBO prevalence was only 8.8% (13 subjects) and, even
though the authors measured both hydrogen andmethane, it was
not specified whether the three patients with methane-positive
SIBO had normal or delayed orocecal transit times. Furthermore,
Sarosiek et al. (91) prospectively enrolled 29 female patients
with functional constipation in a 2-week lubiprostone trial.
Gastrointestinal transit and SIBO were assessed by the wireless
motility capsule (WMC) and lactulose hydrogen/methane breath
tests, respectively. At baseline, 68% of patients had increased
levels of both hydrogen and methane, suggesting SIBO. After
treatment, 41% of patients became SIBO-negative, which was
paralleled by a 30% increase in small bowel transit time. However,
it is important to mention that the authors considered methane
positivity as an increase of ≥3 ppm, which differs from the
current guidelines in which methane positivity is defined as an
increase of≥10 ppm (92). These findings are difficult to interpret
for two reasons: (1) all patients had constipation and were
methane producers at baseline (i.e., methane production of ≥3
ppm); thus, this suggests constipation may have been caused by
intestinal methane production rather than constipation leading
to SIBO; or simply, the methane values present in these patients
could be physiological; and (2), the fact that lubiprostone “cured”
41% of SIBO patients suggests that by increasing the intestinal
transit–and thus intraluminal clearance–faecal stasis decreases,
which prevents SIBO development.
Anatomical Alterations
Anatomical boundaries are crucial for maintaining a harmonized
microbial community within the human alimentary tract,
particularly the integrity of the ileocecal valve. Absence or
dysfunction of the ileocecal valve has been shown to predispose
patients to SIBO, as colonic bacteria are thought to be
“backwashed” into the small intestine, thereby leading to
coliform-type SIBO development (31).
Paediatric intestinal failure is a disease characterised by
increased SIBO prevalence, which is thought to be due to a
multifactorial process that includes altered intestinal motility
and anatomy, resection of the ileocecal valve, and use of
antacids (93, 94). Only four recent studies have investigated
SIBO incidence/prevalence in children with intestinal failure
(or short bowel syndrome) (16–19). The most recent study
by Hong et al. (19) found a 78% SIBO prevalence in their
patient cohort of children who underwent extensive small bowel
resections due to midgut volvulus. Interestingly, only 22% of
patients had a functional ileocecal valve. Moreover, Galloway
et al. (18) diagnosed SIBO by duodenal aspirate cultures in 43%
of patients with intestinal failure, caused mainly by gastroschisis,
atresias, and necrotizing enterocolitis. Of these, only one subject
had an ileocecal valve (16%). Furthermore, Gutierrez et al.
(17) diagnosed SIBO in 70% of patients with intestinal failure
due to various surgical and non-surgical aetiologies. Although
the authors did not find a significant difference regarding
SIBO prevalence between children with and without ileocecal
valve, they did find a significant association between parenteral
nutrition (PN) use and SIBO. The fourth study by Cole et al. (16)
found a 50% SIBO incidence in their patient cohort of children
with short bowel syndrome caused by necrotizing enterocolitis.
Of these, 40% of children had a functional ileocecal valve. In
line with the findings by Gutierrez et al. (17), another interesting
study (95) that evaluated the faecal gut microbiota of children
with short bowel syndrome by next generation sequencing found
that children who were on PN had decreased diversity and
increased numbers of Proteobacteria as compared with those
who were weaned from PN. None of the PN-patients had an
ileocecal valve and, of these, four out five patients were being
evaluated for SIBO and were being treated with antibiotics, which
may explain the microbiota perturbations observed.
Taken together, these findings demonstrate that paediatric
intestinal failure is a multifactorial process that increases the risk
of SIBO, as these children have a disrupted intestinal anatomy,
physiology, and microbiota which is frequently exposed to
antacids and antibiotics. Resection of the ileocecal valve, in
particular, appears to be a common finding in children with
intestinal failure and SIBO, strongly suggesting the role of this
structure in SIBO prevention. In line with this, Roland et al.
(96) investigated the ileocecal junction pressure by WMC and
the presence of SIBO by the LHBT and small bowel aspirate
cultures. Interestingly, the authors found a combination of
SIBO-predisposing factors in their patient cohort: (1) the small
bowel transit time in SIBO-patients was significantly slower
that those without SIBO; (2) the gastric pH was significantly
higher in SIBO-patients than those without SIBO; and (3)
the mean ileocecal junction pressure was significantly lower
among SIBO-patients than those without SIBO. Thus, these
findings reinforce the fact that an “incompetent” ileocecal valve
predisposes to SIBO and emphasise the multifactorial nature
of the disease.
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Impoverished Conditions and Poor
Socioeconomic Status
Impoverished conditions, which are commonly associated with a
lack of basic sanitation services such as clean water, appropriate
sewage, and collection of household garbage, may be a risk
factor for SIBO. To our knowledge, six studies [one from
Myanmar (21), three from Brazil (22–24), and two from
Bangladesh (25, 26)] have investigated this association in the
paediatric population.
Pereira et al. (21) investigated the prevalence of SIBO in
children from a Burmese village (Myanmar) by using the
LHBT. Around 85% of the village’s population obtained drinking
water from surface wells and ponds, and approximately 10%
used rain water for the same purposes (97). The authors
diagnosed SIBO in 27% of cases (53/195), with males being
more commonly affected than females. Moreover, dos Reis
et al. (22) found a significantly higher SIBO prevalence in
children living in a slum as compared with controls living
in households with appropriate sanitation services (37.5 vs.
2.1%, respectively). In addition, Mello et al. (23) also found
a significantly higher SIBO prevalence in the slum-group
compared with their socioeconomically advantaged counterparts
(30.9 vs. 2.4%, respectively); however, it is important to note
that the authors did not find statistically significant differences
in the environmental variables (i.e., water contamination with
coliforms, access to public water network, access to public
sewage, and public collection of household garbage) between the
SIBO-positive and SIBO-negative slum subgroups. The second
and more recent study by Mello et al. (24) assessed SIBO
prevalence and analysed the faecal gut microbiota of children
residing in a Brazilian slum. Roughly 60% of children were found
to have SIBO, and their faecal gut microbiota analyses showed
a significantly higher number of Salmonella spp. and lower
numbers of Firmicutes. Donowitz et al. (25), who investigated
SIBO prevalence in 90 Bangladeshi children belonging to the
lowest socioeconomic strata, reported that 16.7% had a positive
GHBT and that the odds of developing SIBO were increased by
the presence of an open drain/sewer outside the home (odds
ratio, 4.78; 95% confidence interval, 1.06 to 21.62). More recently,
Gaffar et al. (26) conducted a prospective nutritional intervention
study on stunted and at-risk-of-stunting Bangladeshi children
living in an urban slum (98), and found SIBO in 14.9%
of subjects.
Taken together, these findings demonstrate that poor
sanitation conditions, particularly contaminated water
exposure, may expose children to a higher risk of developing
SIBO. However, none of these studies provided a clear
pathophysiological mechanism by which such unsanitary
conditions predispose children to the disease. Donowitz et al.
(55) proposed a mechanism of SIBO development in the setting
of poor sanitary living conditions. The authors hypothesised
that repeated exposure to abnormal levels of liposaccharides
found in soil and drinking water may disrupt the MMC,
causing faecal stasis (as seen in patients with gut dysmotility),
thereby leading to SIBO development. While this theory
appears to have some biological plausibility, to date, no studies
have evaluated it.
Other SIBO Risk Factors
Immunodeficiency and coeliac disease (CD) have also been
regarded as potential risk factors for SIBO development. As
for immunodeficiency, we only identified one small-scale
study (44) from 1990, which was conducted on children
with immunodeficiency syndromes (i.e., IgA deficiency,
hypogammaglobulinemia, and T cell defects). The most
common clinical manifestation was chronic diarrhoea and SIBO
was diagnosed in 41% of patients via jejunal aspirate culture.
Moreover, in a more recent study (99), 4% (n= 12/296) of young
adults with chronic diarrhoea and malabsorption syndrome were
found to have hypogammaglobulinemia. Of these, 25% (n =
3/12) were diagnosed with SIBO. Although these findings show
a relatively high SIBO prevalence in children and young adults
with immunodeficiency syndromes, recent, large-scale studies
are needed in order to support this association. As for CD, a
recent systematic review (100) of adult patient studies found a
high SIBO prevalence in patients with CD (20% pooled mean
prevalence). The authors concluded that SIBO may be more
common in patients with CD when symptoms do not improve
after a gluten-free diet. We identified only two studies (101, 102)
that characterized the microbiota composition and diversity of
children with CD: subjects with active CD were found to have
a higher abundance of members of the phylum Proteobacteria
(101) and lower ecological indexes of genus Lactobacillus (102)
as compared with healthy and non-active CD patients. Although
these studies did not set out to evaluate SIBO per se and as such
did not report CFU/g, the higher Proteobacteria abundance
and lower ecological indexes of genus Lactobacillus seen in
children with CD may indicate a disturbed microbial ecosystem.
Certainly, a study that evaluates the presence of SIBO in coeliac
children, either by the H2/CH4 breath test or small intestinal
aspirate culture, would be of great interest.
It is important to note, however, that SIBO can develop even
in the absence of any of the aforementioned risk factors. In line
with the findings by Boissieu et al. (3) and our own experience,
many children who test positive for SIBO are “healthy” and have
no evident risk factors. There are clearly many questions to be
addressed by future studies regarding the risk factors for SIBO
in children.
AETIOLOGY OF PAEDIATRIC AND ADULT
SIBO
SIBO can be caused by archaea or bacteria, by one or more
microorganisms, by Gram-positive or Gram-negative bacteria,
and by anaerobic or aerobic microorganisms (31). Pistiki et al.
(103) conducted a cross-sectional study in which patients
underwent duodenal aspirate cultures for the diagnosis of
SIBO with a diagnostic threshold of >103 CFU/mL. SIBO was
diagnosed in 20% of cases, being caused by one microorganism
in 54.7% of cases and by two microorganisms in the remainder.
In addition, the vast majority of bacterial isolates belonged
to the phyla Proteobacteria and Firmicutes, with the most
common being Escherichia coli, Enterobacter spp., Klebsiella spp.,
Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter
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baumannii, Stenotrophomonas maltophilia, Citrobacter freundii,
Serratia marcescens, and Enterococcus faecium (in descending
order of frequency). In turn, Pyleris et al. (104) conducted a
study with the same diagnostic methodology, finding SIBO in
19.4% of adult subjects. Likewise, most bacterial isolates were
members of the Proteobacteria and Firmicutes phyla (Escherichia
coli, Enterococcus spp. Klebsiella pneumoniae, Proteus mirabilis,
Acinetobacter baumannii, Citrobacter freundii, and Serratia
marscecens), and in 75% of cases the overgrowth was due to one
microorganism. In the remainder of cases, SIBO was caused by
two microorganisms, with the most common dyads being E. coli
+ K. pneumoniae and E. coli + Enterococcus spp. Furthermore,
Gutierrez (17) conducted a retrospective study on children with
intestinal failure who underwent duodenal aspirate cultures.
SIBO was diagnosed in 70% of cases by using a more stringent
diagnostic threshold of>105 CFU/mL. Again, the most common
causative microorganisms were members of the Proteobacteria
and Firmicutes phyla, with the most common being E. coli,
Streptococcus viridans, K pneumoniae, Enterococcus spp., and
Pseudomonas aeruginosa. The overgrowth was due to more than
one bacterium in a minority of patients. Moreover, Galloway
(18) diagnosed SIBO in 43% of children with intestinal failure, of
whom five out of six patients had overgrowth due to two different
microorganisms and only one had overgrowth caused by one
microorganism, with Enterococcus and Klebsiella being the most
frequently isolated bacteria.
More recently, Ghoshal et al. (105) conducted a cross-
sectional study on adult subjects with non-alcoholic
steatohepatitis (NASH) who underwent a GHBT coupled with
jejunal aspirate cultures. The authors defined SIBO as a bacterial
growth of ≥105 CFU/mL and low-grade bacterial overgrowth as
≥103 CFU/mL; 20 and 60% of cases were diagnosed with SIBO
and low-grade bacterial overgrowth, respectively. Amongst the
SIBO cases, Proteobacteria (Pseudomonas aeruginosa, Klebsiella
pneumonia, and Acinetobacter spp.) were the most commonly
isolated microorganisms followed by members of the Firmicutes
phylum (Streptococcus spp. and Enterococcus faecalis); 20% of
cases were due to overgrowth of more than one microorganism.
Taken together, these findings demonstrate that in most cases,
SIBO is caused by a single microorganism that belongs to
the Proteobacteria phylum (37), particularly coliform bacteria
such as E. coli and Klebsiella spp. However, it is important to
consider three aspects: (1) culture-dependant approaches were
used in these studies, which means that there was a risk of
missing bacteria that remain difficult to culture under clinical
laboratory conditions; (2) only two studies were conducted on
children (17), and (3) SIBO was studied in a wide spectrum
of clinical contexts, such as IBS, intestinal failure, and non-
alcoholic steatohepatitis. Thus, the specificity of such microbiota
alterations for SIBO must be interpreted in the context of these
potentially important confounders.
Next generation sequencing (NGS) methods such as 16S
ribosomal RNA (rRNA) sequencing have become a high-
resolution and relatively cost-effective way to study the human
gut microbiome (106–108). To our knowledge, only one
study in children (6) has used these methods to evaluate
the gut microbiota in the context of SIBO. Vonaesch et al.
(6) conducted a novel, cross-sectional study on stunted and
healthy children from Madagascar and Central African Republic
(CAR), in which 16S rRNA amplicon sequencing was used
to analyse the faecal gut microbiota composition of both
groups and to confirm the presence of bacteria identified by
gastric and duodenal fluid aspirate cultures—these were only
obtained from the stunted group due to ethical reasons. The
authors used the higher diagnostic threshold for SIBO diagnosis
(i.e., >105 CFU/mL). Despite this, SIBO was diagnosed in
96% of stunted children (Madagascar: 100%; and CAR: 88%)
and, interestingly, the most common causative microorganisms
were oropharyngeal colonizers, such as Streptococcus spp.,
Staphylococcus spp., Haemophilus spp., Moraxella spp., and
Neisseria spp. In addition, microbiota sequencing showed
overrepresentation of oropharyngeal species (e.g., Streptococcus
spp., Haemophilus spp., Neisseria spp., Rothia spp., Actinomyces
spp., and Gemella spp.) and enteropathogens (e.g., Escherichia
coli, Shigella, and Campylobacter), as well as underrepresentation
of butyrate producers (e.g., Clostridia spp.) in stunted children
compared with controls. In contrast with the studies described
above (17, 103–105), however, most bacterial overgrowths were
caused by members of the Firmicutes phylum followed by the
Proteobacteria phylum.
CLINICAL FEATURES AND
COMPLICATIONS OF SIBO IN CHILDREN
Paediatric SIBO is a heterogenous disorder that manifests itself
through non-specific symptomatology, including gastrointestinal
and non-gastrointestinal symptoms (31, 109). Themost common
signs and symptoms reported in the literature are chronic
abdominal pain, abdominal distention, diarrhoea, flatulence,
belching, steatorrhea, fetid stools, mucus in stools, fatigue,
nausea, and stunted growth (Table 1) (2–6).
SIBO and Functional Gastrointestinal
Disorders
It is always challenging to discuss functional gastrointestinal
disorders (FGIDs) and their possible interaction with an organic
aetiology, such as SIBO. A small number of observational studies
have evaluated the association between FGIDs and SIBO in the
paediatric population.
Korterink et al. (4) determined the presence of SIBO in
children with abdominal pain–related functional gastrointestinal
disorders [i.e., irritable bowel syndrome (IBS), functional
abdominal pain (FAP), functional dyspepsia (FD), and FAP
syndrome] by using the GHBT. Amongst the 14.3% SIBO-
positive subjects, the most common symptoms were fatigue
(75%), altered defecation pattern (71%), nausea (68%), and
bloating (66%). However, only altered defecation pattern, loss
of appetite, and belching were significantly higher than SIBO-
negative subjects; diarrhoea and flatulence did not reach
statistical significance. Furthermore, Collins et al. (46) also used
the hydrogen/methane breath test to diagnose SIBO in their
cohort of children with chronic abdominal pain (i.e., FD, IBS, and
FAP). Ninety one percent of cases and 35% of healthy controls
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had a positive breath test, respectively. Surprisingly, there were
no differences in the presence of gastrointestinal symptoms such
as bloating, gas, incomplete evacuation, constipation, diarrhoea,
mucous in stool, or straining, between SIBO-positive and SIBO-
negative subjects; however, it is important to mention that
the comparison was disproportional between the two groups
(68 vs. 7 patients, respectively). Moreover, Scarpellini et al.
(45) evaluated the prevalence of SIBO in children with IBS by
the lactulose hydrogen/methane breath test, finding a higher
prevalence of SIBO amongst IBS sufferers compared to their
healthy counterparts (65 vs. 7%, respectively). Taken together,
these findings demonstrate that SIBO is a frequent underlying
diagnosis in children with functional abdominal pain disorders
(i.e., IBS and FD), thus suggesting a role in their pathogenesis.
The IBS-SIBO interaction has attracted a tremendous amount
of research in the last decade, and thus it deserves special
attention. A recent systematic review and metanalysis (110) of
observational studies in adults estimated the prevalence and
determined predictors of SIBO in IBS. The authors found an
overall pooled SIBO prevalence of 38% (95% CI 32–44) as well
as a 4.7 (95% CI 3.1–7.2) pooled OR of SIBO in IBS subjects as
compared with healthy controls. Surprisingly, PPI use was not
associated with SIBO. Even though a growing body of literature
shows a clear association between the two disorders, it is unclear
whether SIBO precedes IBS or vice versa (111, 112). Thus,
until better data are available, children presenting with IBS-like
symptomatology may merit SIBO-diagnostic workup, such as
a H2/CH4 breath test [SIBO’s role in IBS is comprehensively
reviewed elsewhere (61, 113)].
Constipation, another FGID, has been associated with
intestinal methane production in adults and children
(methanogenic SIBO) (114) Indeed, a 2011 metanalysis (115)
of nine studies (1,277 subjects) found a significant association
between methane on breath test and constipation (OR 3.51, CI
2.00–6.16). Moreover, Pimentel et al. (116) demonstrated this
association in animal and human models: intraluminal infusion
of methane reduced small bowel transit by 59% in canine models
as compared with controls, and methane was also found to
increase intestinal contractile activity in guinea pigs and in
patients with IBS. In contrast, Mello et al. (23) did not find an
association between methane and constipation in their patient
cohort of children living in a slum; in fact, none of these children
had constipation despite a 30% prevalence of methanogenic
SIBO.More recently, Ghoshal et al. (117) investigated the effect of
rifaximin on breath methane and colonic transit in adult patients
with constipation. The authors found that a larger percentage
of patients with chronic constipation were methane producers
(>10 ppm) and had slower colonic transit times as compared
with controls. Methane producers (n = 13) were randomly
assigned into two groups: rifaximin group (14-day trial) and
placebo group. After treatment, the rifaximin group had a
significantly lower area under the curve for methane production
compared with the placebo group, and colonic transit time
normalized in 66% of cases as compared with the placebo group,
in whom colonic transit time never normalized. Thus, these
findings support the association between methanogenic SIBO
and constipation. The most important question to be answered
is whether it would be cost-effective to perform methane breath
tests on all children with “functional” constipation, considering
the relatively high prevalence of the disease. What we know from
small scale studies is that children with constipation and retentive
faecal incontinence are more likely to be methane producers than
children with constipation alone (15, 20). Thus, possibly, these
children may benefit from antibiotic therapy. However, large
scale, prospective studies are warranted in order to (1) clarify
the relation between methanogenic SIBO and constipation, and
(2) determine whether children with methanogenic SIBO and
constipation may benefit from antibiotic treatment.
SIBO and Systemic Disorders
Increasing evidence suggests that SIBO may be implicated in
the complex pathophysiology of stunted growth (6, 25) and
environmental enteric dysfunction (EED; formerly known as
environmental enteropathy) (24, 55, 56, 60). Stunting affects
>30% of children under five from low income countries (118).
As shown in Figure 3, intraluminal competition for micro and
macronutrients between the excessive bacterial biomass and the
host (119), as well as other SIBO-induced factors (e.g., diarrhoea,
carbohydrate malabsorption, protein loss, increased intestinal
permeability, intestinal and systemic inflammation), can lead to a
negative caloric balance in the host, thereby, resulting in stunted
growth and malnutrition. Such factors, too, characterise EED,
thus it appears that SIBO may play an important role in EED’s
pathogenesis (6, 120). Vonaesch et al. (6) diagnosed SIBO in 96%
of their patient cohort of children with stunting by the GHBT.
In addition, Donowitz et al. (25) found a 16.7% SIBO prevalence
in Bangladeshi children using the same diagnostic methodology.
Taken together, these findings suggest a possible role of SIBO in
stunting and EED’s pathogenesis. Thus, it may be worthwhile to
perform a hydrogen/methane breath test as part of the clinical
approach to children with these diseases.
Moreover, although deficiencies of liposoluble vitamins (A,
D, and E) and vitamin B 12 haven been documented in the
adult population (121, 122), no studies have explored this issue
in children with SIBO—a study assessing vitamin B12 and
liposoluble vitamin status in children affected by SIBO would be
of great interest. Menaquinone (vitamin K2) is produced by the
gut microbiota (123), and thus from a physiological standpoint
it would be contradictory to assume that vitamin K deficiency
would arise in a bacterial-abundant environment. However, a
recent case report described a 17-year-old female with vitamin K
deficiency possibly caused by SIBO. The authors speculated that
the vitamin K deficiency seen in this patient may have been the
result of reduced menaquinone-producing bacteria, expansion of
vitamin K-consuming bacteria, or severe malabsorption (124).
Further gut metabolome studies (125) are needed to elucidate
SIBO’s role in vitamin deficiencies.
Currently, there are no guidelines regarding diagnosis or
treatment of SIBO in children. Given the heterogenous and non-
specific nature of the disease, it is sometimes challenging to
decide in whom to initiate SIBO diagnostic work-up. However, it
is of paramount importance to first rule out signs and symptoms
(i.e., red flags) that may indicate diseases other than SIBO.
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DIAGNOSIS
SIBO can be diagnosed by invasive and non-invasive
methods. The non-invasive methods include breath tests,
while invasive methods comprise culture-dependant and
culture-independent approaches.
Hydrogen and Methane Breath Testing
Although subject to debate and controversy (126–128), the
H2 and CH4 breath tests are increasingly being used due to
their widely availability in healthcare facilities, because they
are inexpensive, practical, and non-invasive (which is extremely
important in paediatrics), and because the results can be
interpreted on the same day of the test [the H2/CH4 breath
test procedure is thoroughly reviewed elsewhere (92, 129, 130)].
According to the 2017 “Hydrogen and Methane-Based Breath
Testing in Gastrointestinal Disorders: The North American
Consensus”(92), a panel of 17 experts from North America and
the latest consensus in regard to this topic, SIBO diagnosis is
suggested when there is an increase in H2 of ≥20 ppm over
baseline within the first 90min of the test with either lactulose
or glucose, or when there is an increase in CH4 of ≥10 ppm
at any time point of the test (Figure 4). On the other hand, the
older Rome Consensus (130) recommends the use of glucose
as substrate due to its greater accuracy, and defines SIBO as
an increase in H2 of ≥12 above baseline by using the GHBT.
A definition of SIBO by using the LHBT was not included in
this paper.
In order to understand the mechanisms behind H2 and
CH4 breath testing, one must be aware of two concepts:
orocaecal transit time and intraluminal gas production. The
human body has no means of producing H2 and CH4 other
than intraluminal microbial fermentation and methanogenesis,
respectively (92, 130–132). As previously mentioned, the colonic
microbiota represents virtually the whole gut microbiota, most
of which is composed of fibre-fermenter anaerobes, mainly
those belonging to the Actinobacteria and Firmicutes phyla
(133). Undigestible carbohydrates reaching the colon are readily
fermented by hydrogenogens (H2-producing bacteria) (134), and
hence a physiological increase in H2 is expected in the colon.
Intraluminal H2, in turn, is absorbed into the systemic circulation
and is transported to the lungs where it can then be released
through exhaled breath (129). Moreover, the orocaecal transit
time—the elapsed time between ingestion of a substance until
it reaches the caecum—has been shown to be around 90min in
both adults and children, as assessed by the LHBT (135). Thus,
in the presence of SIBO, substrate administration will result in a
small bowel H2 peak, occurring before the orocaecal transit time
has completed (i.e., 90 min).
Glucose and lactulose are the substrates usually used for
breath tests to diagnose SIBO. The former is a monosaccharide
which is readily absorbed in the proximal small intestine, and
the latter is a synthetic, undigestible disaccharide that reaches the
caecum intact. In the presence of SIBO, glucose administration
will result in a H2 peak which is produced in the small intestine
(i.e., <90min); in addition to this peak, lactulose administration
can give rise to a second –colonic– H2 peak: the early peak
produced by the bacterial overgrowth in the small intestine and
the second one caused by the colonic microbiota fermentation
(92, 129). However, both substrates have their own advantages
and limitations. By using glucose, false negative results can
arise in the presence of bacterial overgrowth in the distal small
bowel (i.e., ileum), as glucose is readily absorbed proximally. In
addition, an increased orocecal transit time can give rise to false
positive results as the substrate reaches the colon rapidly, thereby
undergoing premature fermentation by colon bacteria—this can
occur with both glucose and lactulose (126). False negative results
can also arise in the absence of H2-producing bacteria or in the
presence of CH4-producing microorganisms (discussed below)
(130). Based on a 2008 systematic review (136), the sensitivity
and specificity of the GHBT ranged from 20 to 93% and 30 to
86%, respectively; and the sensitivity and specificity of the LHBT
ranged from 31 to 68% and 44 to 100%, respectively.
Methanobrevibacter smithii, a member of the domain
Archaea and the most abundant methanogen in the human
alimentary tract produces CH4 as an end product of hydrogen
metabolism (hydrogenotrophic methanogenesis), by using
one molecule of carbon dioxide and four molecules of
H2. The archaeon is extremely oxygen sensitive and relies
completely on hydrogenogens for CH4 production, due to
its inability to metabolise monosaccharides. For this reason,
Methanobrevibacter smithii is considered an “obligate cross-
feeder” (131). Furthermore, since the archaeon utilizes H2 to
produce CH4, it can lead to a falsely negative HBT. Thus, it is
recommended that both H2 and CH4 are measured in order to
avoid this (92).
In conclusion, despite the limitations of the H2/CH4 test
(128), it remains a useful tool in the diagnosis of paediatric SIBO
due to its practical and non-invasive nature. Importantly, there
are no reported significant side effects for the hydrogen/methane
breath test other than transient abdominal pain or vomiting
during the test.
Culture-Dependant Approaches
Culture-dependent approaches are considered the current gold
standard for definitive SIBO diagnosis. A small intestinal
(i.e., duodenum or jejunum) aspirate is obtained at upper
gastrointestinal endoscopy through a sterile catheter and stored
anaerobically prior to culture for both aerobic and anaerobic
bacteria. When using the proximal jejunal aspirate culture,
a bacterial concentration of >103 CFU/mL is regarded as
indicative of SIBO (92, 109), although there is some heterogeneity
in the literature in this regard and some experts recommend
a threshold of >105 CFU/mL as more specific (137). Despite
being regarded as the gold standard diagnostic method, there are
several notable limitations to this approach. Firstly, endoscopy-
guided aspiration procedures are invasive, expensive, and require
specialist input, limiting its availability and application in certain
settings. Secondly, we know from microbiome research that
standard clinical laboratory culture-based approaches have the
potential to detect only a minority of the extant bacterial
consortium. In addition, care must also be taken not to
contaminate samples or sampling apparatus with oropharyngeal
microbes, thereby contributing to false positives. Likewise,
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FIGURE 4 | Graphical representation of the hydrogen and methane breath tests. The vertical dotted line indicates the completion of the orocecal transit time, and the
horizontal dotted line indicates the current diagnostic thresholds for SIBO. The green shaded areas indicate where the test is considered positive. Created with
BioRender.com.
the significant heterogeneity in aspirate sampling protocols
are known to impact substantially on the test outcome and
accuracy. For example, one study previously used air, rather
than nitrogen or carbon dioxide, during endoscopy to recover
aspirate samples in suspected SIBO and cultured anaerobic
bacteria from just one of 50 samples (138). Other variables
include specific site of sampling and volume of aspirate. The lack
of standardised protocol and diagnostic consensus for the gold
standard investigation undoubtedly contributes to the massive
variation in the SIBO prevalence and incidence rates reported
in the literature. This, in turn, limits comparability between
studies and ultimately hinders research progression in the field.
In order for the development of a greater understanding and
novel therapies for the disease to arise, the disparities in protocols
and diagnostic criteria should first be addressed at a global scale.
Finally, in the context of paediatric SIBO, endoscopy of seemingly
healthy control children appears to present an obstacle in clinical
research studies due to ethical considerations and, therefore,
development of less invasive diagnostic approaches is warranted.
SIBO in the Era of Next Generation
Sequencing
As eluded to previously, culture-independent approaches based
on NGS technologies have become the most widely applied
modalities for studying both the composition and metabolic
activity of the gut microbiota. There are several considerations
to be addressed when selecting a methodology, including
sample type, DNA extraction method, sequencing modality
and platform, as well as bioinformatic pipeline [reviewed
comprehensively in (43)].
In general, the composition of the gut microbiota is currently
most cost effectively studied through 16S rRNA sequencing. The
16S region is a highly conserved region of rRNA within all taxa
of bacteria, which displays sufficient variation and divergence
in parts to allow differentiation at the genus level. Although it
has been central to the progression of the field of microbiome
research, 16S rRNA sequencing is crucially limited in the fact
that it does not generate absolute data on quantities of bacteria,
but rather provides investigators with a relative abundance of
each taxa within a sample. The second modality which is indeed
worthy of consideration is metagenomic shotgun sequencing.
While 16S rRNA sequencing provides an overview of microbiota
composition, metagenomic shotgun sequencing goes a step
further by telling us who is there and what are they capable of
in metabolic terms.
Although such sequencing capabilities are now commonplace
in microbiological and medical research laboratories the globe
over, uptake and application to SIBO research has been
comparatively slow and, as a result, there is a dearth of
relevant clinical data available. Despite this, several clinical
studies which targeted alternate, but related, gastrointestinal
disorders have provided some intriguing data on the disorder.
In line with this, some small studies have reported on
the gut microbiome of IBS cohorts, many of which were
confirmed to suffer from concomitant SIBO. One such study
investigated the faecal microbiota of a cohort of 30 Chinese
patients with diarrhoea-predominant IBS, 14 of which were
also confirmed to have SIBO by LHBT (139). At baseline,
this cohort displayed reduced microbiota diversity, increased
relative abundances of Bacteroidetes and decreased relative
abundances of Firmicutes when compared to the healthy
controls. In addition, the IBS cohort was shown to have
reduced relative abundances of the genus Lactobacillus, as well
as several genera associated with butyrate production. The
investigators subsequently implemented a 2-week course of
rifaximin, after which clinical symptoms improved and repeat
LHBT demonstrated remission in 65% of the SIBO-positive
subjects. However, the microbiota post-treatment displayed only
minor alterations in taxa for which little metabolic information
is available, a result which was mirrored previously in similarly
designed trials of rifaximin in IBS (140, 141). Indeed, it must be
reiterated that less than half of the IBD cohort studied in this
trial were confirmed to have concomitant SIBO and the samples
investigated (i.e., faeces) bears little resemblance to the site most
relevant to the disease; therefore, no definitive conclusions on
SIBO pathogenesis should be drawn from this data.
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With regards to SIBO in children, one study outlined above
aimed to investigate the microbiota in sub-Saharan children
with stunted growth (6). In addition to faecal microbiota
analysis, it was deemed pertinent to retrieve and analyse the
microbiota of small intestinal aspirates, due to its role in nutrient
absorption and malnutrition. The authors declared a form of
microbial “decompartmentalization,” in which oropharyngeal-
associated microbes were found to be over-represented in the
small intestine of these children, 91% of which tested positive for
SIBO. Although this was deduced primarily from culture-based
methods, it is consistent with preliminary reports suggesting
that SIBO is not caused by migratory colonic microbes (142).
In turn, 16S rRNA sequencing of the duodenal microbiota in
these subjects revealed a community containing near-equal parts
Proteobacteria (32.4%), Bacteroidetes (29.6%), and Firmicutes
(25.6%), with lesser portions of Fusobacteria (9.2%), and
Actinobacteria (1.7%). Critically, however, this study was severely
limited by the fact that there are no appropriate controls available
for themicrobiota analysis of duodenal aspirates, presumably due
to ethical considerations. Therefore, we are left, once again, with
half-truths and a degree of speculation on the potential role and
composition of the small intestinal microbiota in SIBO.
These studies demonstrate that SIBO has been regarded
largely as a sign or sequela of a gastrointestinal disorder,
rather than a discrete disorder in itself. This perspective
has meant that the pathogenesis of SIBO has sparsely
been addressed directly, but rather has been of peripheral
interest in studies with an intersecting interest. Having said
this, perhaps the most informative characterisation effort of
SIBO to date has come from a recent investigation of 126
adults displaying gastrointestinal symptoms (66 SIBO positive
and 60 SIBO negative) (143). The authors uncovered that,
although duodenal aspirate culture results do not correlate
with symptoms, the aspirate microbiome was significantly
altered in symptomatic participants. This altered microbiome
is characterised primarily by decreased levels of the genus
Prevotella and enhanced microbial metabolism of ascorbic
acid. In addition, it was identified that age, recent antibiotic
exposure, PPI use and diet were the major proponents in
the disruption of the microbiome and onset of symptoms. In
line with this, the investigators demonstrated that a dietary
fibre restriction intervention in healthy high-fibre consuming
individuals had significant effects on the microbiome and
triggered gastrointestinal symptoms common to SIBO. This
study identifies several potentially targetable components of
SIBO pathogenesis and represents an excellent blueprint for the
future study of the disease.
TREATMENT
Due to the relative inaccessibility of duodenal samples for culture
and difficulty in differentiating the culpable microorganism in a
diverse ecosystem such as the small intestine, antibiotic therapy
is generally initiated on an empiric basis. A 2013 systematic
review and meta-analysis of antibiotic use in the context of SIBO
found that rifaximin was by far the most commonly applied
(144). While the meta-analysis ruled in favour of antibiotic use
over placebo (effectiveness ratio 2.55, CI 1.29–5.04), rifaximin
failed to reach a significant superiority (effectiveness ratio
1.97, CI 0.93–4.17). However, just three studies were deemed
appropriate for this analysis and their heterogeneity limit the
usefulness of this result. In line with this, the systematic
review went on to reveal that monotherapy with 1,200 mg/d
rifaximin was efficacious, at 60.8% remission. Moreover, the
antibiotic reached a substantially heightened efficacy of 85%
when combined with partially hydrolysed guar gum, albeit in
a single trial. Two studies included in the systematic review
investigated the use of metronidazole, demonstrating a return
to normal breath test in 51% of SIBO patients; while a single
small study reported remission in all 14 patients recruited and
treated with ciprofloxacin.
A more recent systematic review and meta-analysis of
rifaximin therapy in SIBO included data from >1,300 patients
(145). A dose-dependent response was demonstrated for
eradication rates and, in line with the previous systematic review,
the most commonly used dose was 1,200 mg/d, with one study
reporting 600 mg/d and another 1,600 mg/d. The investigators
found an overall eradication rate of 70%, with adverse events
reported in < 5%. In addition, in a subset of studies which
assessed symptom severity and resolution, meta-analysis revealed
remission from symptomology in 68% of patients who were
found to be successfully eradicated of SIBO. These studies
demonstrate the efficacy and safety of rifaximin in the treatment
of SIBO and its symptoms.
While the studies included in the above meta-analysis
were all conducted with adult cohorts, one study previously
investigated the use of rifaximin in children (48). Applying a
regimen of 600 mg/d for 1 week, the investigators reported
a rate of 64% (n = 21/33) in breath test normalisation
response. In light of the limited available data, a dose response
study of rifaximin in a paediatric population would indeed
be of interest. Finally, one study investigated the efficacy
of a combination regimen of trimethoprim-sulfamethoxazole
(TMP-SMT; 30mg kg1 d1) and metronidazole (MTZ; 20mg
kg1 d1) twice daily for 2 weeks in slum-dwelling children
suffering from SIBO (146). When retested for SIBO by
breath test 1 month after commencement of this therapy, the
authors noted 95% (n = 19/20) resolution of the disorder.
However, the lack of a placebo or non-intervention control
group limits assessment of temporal effects on SIBO status.
Taken together, these results indicate that antibiotics are an
effective means of treating SIBO in children and, although
non-rifaximin antibiotics appear to produce greater resolution,
the data is weaker for such medications and rifaximin has
demonstrated safety in a greater number of participants
and studies.
While antibiotics remain the first-line and gold-standard
approach to SIBO management, there are additional or
alternative approaches that may have application in the future,
but the efficacy of which remains uncertain at present.
For instance, there is biologic plausibility to the hypothesis
that there may be a role for low FODMAP (Fermentable
Oligosaccharides, Disaccharides, Monosaccharides, and Polyols)
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diets in decreasing fermentable substrates in the context
of SIBO. Low FODMAP diets aim to greatly deplete or
entirely eliminate the highly fermentable simple carbohydrates
which are commonly found in certain dairy products, fruits,
vegetables, nuts and legumes, with the ultimate aim of
graded reintroduction of specific FODMAPs to elucidate the
culpable source (147).
Interestingly, probiotics have also previously been considered
as potential agents in the management of SIBO (148). In
line with this, a more recent meta-analysis evaluating the
efficacy of this avenue revealed that probiotic intervention
resulted in vastly reduced H2 levels (WMD −36.35, CI
−44.23−28.47) and increased rates of decontamination
(RR 3.29, CI 1.47–7.36) when compared to placebo. More
intriguingly, however, is that probiotics also demonstrated more
favourable results when compared directly to metronidazole
treatment (RR 1.49, CI 1.07–2.08). Despite this, the best results
overall were obtained when probiotics were combined with
rifaximin or minocycline.
Finally, there is some evidence to suggest that certain statins
may have a role in depleting Methanobrevibacter spp., thereby
offering a novel therapy for methane-specific SIBO (149, 150).
In line with this, a modified-release formulation of lovastatin,
termed SYN-010, has been created to deliver the drug in a
biphasic manner during transit, thereby avoiding considerable
degradation and absorption in the upper gastrointestinal tract
(151). A dose of 42 mg/day of SYN-010 for as little as seven days
was demonstrated to significantly reduce methane production
when compared to placebo in a multi-centred double-blind RCT
(152). Moreover, this promising therapy recently entered an
efficacy and safety trial in patients with IBS (ClinicalTrials.gov
ID: NCT03763175). The effect of this drug appears to be
primarily due to the HMG-CoA reductase inhibition attributes
of statins, thereby preventing the formation of mevalonate, a
primary precursor in of key membrane lipids specific to archaea.
This mechanism, along with several others, has been previously
reviewed extensively elsewhere (41), and so, will not be discussed
further herein.
PROGNOSIS
At present, it is unclear whether the gut microbiota changes that
characterise paediatric SIBO have detrimental effects in the long-
term. In order to shed light on the long, and even short-term
prognosis of children with SIBO, large scale, prospective studies
are warranted.
CONCLUSION
Herein, we attempted to synthesise the most current literature on
paediatric SIBO, from a gut microbiota perspective. Paediatric
SIBO is a heterogenous and poorly understood entity, whose
prevalence and incidence are difficult to determine due to the
lack of uniformity and consensus of its diagnostic criteria.
However, based upon the available literature, it appears that
SIBO is a common underlying diagnosis in children who
present clinically with certain FGDs and stunted growth, and
in children with history of acid suppressive therapies, intestinal
motility disturbances, anatomical alterations, or impoverished
conditions. Further research with integration of culture-
dependant and culture-independent approaches is needed in
order to (1) understand paediatric SIBO pathogenesis, clinical
presentation, and prognosis, and (2) establish global consensus
on the diagnostic criteria for SIBO.
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